Submitted:
22 January 2024
Posted:
25 January 2024
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
2.1. Participants and Procedures
2.2. Endpoints
- the occurrence of distant metastases;
- the occurrence of metastases at the level of the sentinel lymph node and/or any other removed lymph node;
- MM specific mortality.
2.3. Statistical analysis
2.4. Software
3. Results
4. Discussion
- In situ melanomas: 0.5 cm of surgical margins of healthy tissue;
- Breslow’ thickness <=1 mm: 1 cm of surgical margins of healthy tissue;
- Breslow’ thickness 1.01-2.00 mm: 1-2 cm of surgical margins of healthy tissue;
- Breslow’ thickness >2 mm: 2 cm of surgical margins of healthy tissue [16].
5. Conclusions
Author Contributions
Funding
Data Availability Statement
Conflicts of Interest
References
- Bolick NL, Geller AC. Epidemiology of Melanoma. Hematol Oncol Clin North Am. 2021 Feb;35(1):57-72. [CrossRef] [PubMed]
- Kahlon N, Doddi S, Yousif R, Najib S, Sheikh T, Abuhelwa Z, Burmeister C, Hamouda DM. Melanoma Treatments and Mortality Rate Trends in the US, 1975 to 2019. JAMA Netw Open. 2022 Dec 1;5(12):e2245269. [CrossRef] [PubMed]
- Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N, Bastholt L, Bataille V, Del Marmol V, Dréno B, Fargnoli MC, Forsea AM, Grob JJ, Hoeller C, Kaufmann R, Kelleners-Smeets N, Lallas A, Lebbé C, Lytvynenko B, Malvehy J, Moreno-Ramirez D, Nathan P, Pellacani G, Saiag P, Stratigos AJ, Van Akkooi ACJ, Vieira R, Zalaudek I, Lorigan P; European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization for Research and Treatment of Cancer (EORTC). European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022. Eur J Cancer. 2022 Jul;170:256-284. [CrossRef] [PubMed]
- Swetter SM, Thompson JA, Albertini MR, Barker CA, Baumgartner J, Boland G, Chmielowski B, DiMaio D, Durham A, Fields RC, Fleming MD, Galan A, Gastman B, Grossmann K, Guild S, Holder A, Johnson D, Joseph RW, Karakousis G, Kendra K, Lange JR, Lanning R, Margolin K, Olszanski AJ, Ott PA, Ross MI, Salama AK, Sharma R, Skitzki J, Sosman J, Wuthrick E, McMillian NR, Engh AM. NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021. J Natl Compr Canc Netw. 2021 Apr 1;19(4):364-376. [CrossRef] [PubMed]
- Giudice G, Leuzzi S, Robusto F, Ronghi V, Nacchiero E, Giardinelli G, Di Gioia G, Ragusa L, Pascone M. Sentinel lymph node biopsy in head and neck melanoma*. G Chir. 2014 May-Jun;35(5-6):149-55. [PubMed]
- Veronesi U, Cascinelli N, Adamus J, et al. Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 melanoma. N Engl J Med 1988;318:1159-1162.
- Urist MM, Balch CM, Soong S, et al. The influence of surgical margins and prognostic factors predicting the risk of local recurrence in 3445 patients with primary cutaneous melanoma. Cancer 1985;55:1398-1402.
- Welvaart K, Hermans J, Zwavelig A, et al. Prognoses and surgical treatment of patients with stage I melanomas of the skin: a restrospective analysis of 211 patients. J surg oncol 1986;31:79-86.
- Thiele C, Hirschfeld G (2021). “cutpointr: Improved Estimation and Validation of Optimal Cutpoints in R”. Journal of Statistical Software, 98(11), 1–27. [CrossRef]
- Fluss R, Faraggi D, Reiser B (2005). “Estimation of the Youden Index and Its Associated Cutoff Point.” Biometrical Journal, 47(4), 458–472. [CrossRef]
- Altman DG, Royston P (2000). “What Do We Mean by Validating a Prognostic model?”Statistics in Medicine, 19(4), 453–473.
- Carpenter J, Bithell J (2000). “Bootstrap Confidence Intervals: When, Which, What? A Practical Guide for Medical Statisticians.” Statistics in Medicine, 19(9), 1141–1164.
- Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370:599–609.
- Pathak S, Zito PM. Clinical Guidelines for the Staging, Diagnosis, and Management of Cutaneous Malignant Melanoma. 2023 Jun 26. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan. [PubMed]
- Giuliano AE, Ballman KV, McCall L, et al. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA. 2017;318:918–926.
- Ethun CG, Delman KA. The importance of surgical margins in melanoma. J Surg Oncol. 2016 Mar;113(3):339-45. [CrossRef] [PubMed]
- Giudice G, Leuzzi S, Robusto F, Ronghi V, Nacchiero E, Giardinelli G, Di Gioia G, Ragusa L, Pascone M. Sentinel lymph node biopsy in head and neck melanoma*. G Chir. 2014 May-Jun;35(5-6):149-55. [PubMed]
- Giudice G, Robusto F, Vestita M, Annoscia P, Elia R, Nacchiero E. Single-stage excision and sentinel lymph node biopsy in cutaneous melanoma in selected patients: a retrospective case-control study. Melanoma Res. 2017 Dec;27(6):573-579. [CrossRef] [PubMed]


| GROUP A* (n=72) |
GROUP B** (n=388) |
p-value | |
|---|---|---|---|
| Sex | |||
| Male | 49(68,06) | 185(50,96) | 0,0094 |
| Female | 23 (31.94) | 178 (49.04) | |
| Age at diagnosis median[IQR] | 54[42-63] | 55[45-66] | 0,745 |
| Hospital | |||
| Policlinico | 51(70,83) | 257(71,59) | 0,8871 |
| Other | 21(29,17) | 102(28,41) | |
| Site of melanoma | |||
| Face | 6(8,33) | 18(5,01) | 0,4775 |
| Head | 1(1,39) | 14(3,9) | |
| Medial face arm | 3(4,17) | 30(8,36) | |
| Dorsal aspect arm | 2(2,78) | 9(2,51) | |
| Palm hand | 1(1,39) | 2(0,56) | |
| Back hand | 0(0) | 6(1,67) | |
| Chest | 8(11,11) | 42(11,7) | |
| Abdomen and anterior groin | 3(4,17) | 21(5,85) | |
| Back | 30(41,67) | 117(32,59) | |
| Buttocks | 1(1,39) | 19(5,29) | |
| Front thigh | 6(8,33) | 41(11,42) | |
| Front leg | 5(6,94) | 17(4,74) | |
| Rear thigh | 1(1,39) | 2(0,56) | |
| Rear leg | 0(0) | 8(2,23) | |
| Back foot | 1(1,39) | 8(2,23) | |
| Plant foot | 4(5,56) | 4(1,11) | |
| Vulva | 0(0) | 0(0) | |
| Ear | 0(0) | 1(0,28) | |
| Type of melanoma | |||
| In situ | 1(1,39) | 47(13,17) | <0,0001 |
| superficial diffusion | 14(19,44) | 167(46,78) | |
| epithelioid | 11(15,28) | 35(9,8) | |
| nodular | 42(58,33) | 80(22,41) | |
| malignant lentigo | 4(5,56) | 26(7,28) | |
| other | 0(0) | 2(0,56) | |
| Clark Stage | |||
| I | 0(0) | 1(0,34) | <0,0001 |
| II | 0(0) | 55(18,9) | |
| III | 11(16,67) | 134(46,05) | |
| IV | 44(66,67) | 92(31,62) | |
| V | 11(16,67) | 9(3,09) | |
| Ulceration | 27(58,7) | 63(31,34) | 0,0011 |
| peritumoral lymphocytic infiltrate | 36(70,59) | 164(70,69) | 1 |
| intratumoral lymphocytic infiltrate | 40(80) | 214(86,29) | 0,275 |
| Class of Breslow | |||
| < 1 mm | 7(11,29) | 126(42,28) | <0,0001 |
| 1-2 mm | 16(25,81) | 80(26,85) | |
| 2,1 - 4 mm | 19(30,65) | 60(20,13) | |
| > 4mm | 20(32,26) | 32(10,74) | |
| Presence of metastases at the wide excision | 7(10,45) | 15(4,29) | 0,0653 |
| Data are show as N(%). * Patients with Composite Endpoint ** Patients without Composite Endpoint | |||
| Univariate Model | Multivariate Model | |||
|---|---|---|---|---|
| HR1 | IC95% | HR1 | IC95% | |
| Presence of metastases at wide excision | 2,23 | 1,02-4,89 | 1,62 | 0,63-4,17 |
| Time from diagnosis to wide excision | 1 | 0,99-1 | 0,99 | 0,97-1,01 |
| sex | 1,99 | 1,2-3,3 | 1,49 | 0,82-2,7 |
| age at diagnosis | 1 | 0,98-1,02 | 0,99 | 0,97-1 |
| Type of melanoma | ||||
| in situ vs surface diffusion | 0,24 | 0,03-1,85 | ||
| in situ vs epithelioid | 0,08 | 0,01-0,67 | ||
| in situ vs nodular | 0,05 | 0,01-0,34 | ||
| in situ vs lentigo maligna | 0,14 | 0,02-1,21 | ||
| superficial spreading vs epithelioid | 0,35 | 0,15-0,8 | ||
| superficial spreading vs nodular | 0,19 | 0,1-0,35 | ||
| superficial spreading vs lentigo maligna | 0,55 | 0,18-1,68 | ||
| epithelioid vs nodular | 0,55 | 0,27-1,13 | ||
| epithelioid vs lentigo maligna | 1,6 | 0,49-5,19 | ||
| nodular vs lentigo maligna | 2,93 | 1,05-8,18 | ||
| lozenge length | 1,08 | 0,98-1,19 | ||
| lozenge width | 1,65 | 1,34-2,04 | 1,46 | 1,03-2,06 |
| lozenge thickness | 1,78 | 1,1-2,88 | ||
| Class of Breslow | ||||
| 1 vs 2 | 0,24 | 0,1-0,61 | 0,23 | 0,09-0,64 |
| 1 vs 3 | 0,17 | 0,07-0,42 | 0,17 | 0,06-0,47 |
| 1 vs 4 | 0,09 | 0,04-0,23 | 0,11 | 0,04-0,32 |
| 2 vs 3 | 0,7 | 0,37-1,33 | 0,74 | 0,37-1,48 |
| 2 vs 4 | 0,37 | 0,19-0,71 | 0,48 | 0,23-1,03 |
| 3v4 | 0,53 | 0,28-0,99 | 0,66 | 0,32-1,34 |
| intratumoral infiltrate | 0,97 | 0,52-1,8 | ||
| Peritumoral infiltrate | 0,64 | 0,32-1,28 | ||
| Site of melanoma | ||||
| head-neck vs limbs | 1.20 | 0.49-2.96 | ||
| head-neck vs torso | 0.94 | 0.40-2.22 | ||
| head-neck vs other | 3.98 | 0.48-33.09 | ||
| Limbs vs torso | 0.78 | 0.46-1.32 | ||
| Limbs vs other | 3.32 | 0.45-24.66 | ||
| Torso vs other | 4.24 | 0.58-30.88 | ||
|
1: adjusted by Wald methods; IC: Confidence interval; HR: Hazard Ratio; Class of Breslow: 1 (<1 mm); 2 (1-2 mm); 3 (2.1-4mm);4(>4mm). | ||||
| Univariate Model | Multivariate Model | |||
|---|---|---|---|---|
| OR | IC95% | OR | IC95% | |
| Time from diagnosis to wide excision [+1day] | 1 | 1-1 | ||
| Sex [male vs female] | 0,98 | 0,42-2,28 | 0,14 | 0,02-0,85 |
| age at diagnosis [+1 year] | 1,06 | 1,02-1,1 | 1,02 | 0,96-1,09 |
| Type of melanoma | ||||
| in situ vs surface diffusion | 6,7 | 1,2-37,6 | ||
| in situ vs epithelioid | 0,47 | 0,12-1,78 | ||
| in situ vs nodular | 0,92 | 0,26-3,18 | ||
| in situ vs lentigo maligna | 0,69 | 0,41-3,31 | ||
| superficial spreading vs epithelioid | 0,07 | 0,01-0,36 | ||
| superficial spreading vs nodular | 0,14 | 0,28-0,66 | ||
| superficial spreading vs lentigo maligna | 0,1 | 0,02-0,65 | ||
| epithelioid vs nodular | 1,95 | 0,64-6 | ||
| epithelioid vs lentigo maligna | 1,47 | 0,34-6,41 | ||
| nodular vs lentigo maligna | 0,75 | 0,19-3,03 | ||
| lozenge length [+1cm] | 1,04 | 0,85-1,27 | ||
| lozenge width [+1cm] | 1,5 | 1,02-2,2 | ||
| lozenge thickness [+1cm] | 2,01 | 1,11-3,65 | ||
| Breslow thickness [+1mm] | 1,36 | 1,15-1,61 | 1,41 | 1,06-1,88 |
| intratumoral infiltrate [Yes vs No] | 0,92 | 0,23-3,67 | ||
| Peritumoral infiltrate [Yes vs No] | 0,39 | 0,1-1,56 | ||
| Ulcerations [Yes vs No] | 18,86 | 2,35-151,7 | ||
| Site of melanoma | ||||
| head-neck vs limbs | 4.2 | 1.41-12.47 | ||
| head-neck vs torso | 8.17 | 2.57-25.94 | ||
| head-neck vs other | 4.67 | 0.53-40.89 | ||
| Limbs vs torso | 1.94 | 0.66-5.72 | ||
| Limbs vs other | 1.11 | 0.13-9.36 | ||
| Torso vs other | 0.57 | 0.06-4.98 | ||
| 1 adjusted by Wald methods; IC: Confidence interval; OR: Odds Ratio | ||||
| Cutpoint | Youden | Accuracy | Sensitivity | Specificity |
|---|---|---|---|---|
| 2.0 mm | 0.41 | 0.67 | 0.75 | 0.66 |
| 2.1 mm | 0.43 | 0.68 | 0.75 | 0.68 |
| 2.2 mm | 0.46 | 0.71 | 0.75 | 0.71 |
| 2.31 mm | 0.5 | 0.75 | 0.75 | 0.75 |
| 2.4 mm | 0.44 | 0.75 | 0.69 | 0.75 |
| 2.5 mm | 0.40 | 0.76 | 0.63 | 0.77 |
| Bag | Out of Bag | |||
|---|---|---|---|---|
| Median | IQR | Median | IQR | |
| AUC | 0,76 | 0,72-0,80 | 0,76 | 0,71-0,81 |
| Accuracy | 0,76 | 0,74-0,78 | 0,75 | 0,72-0,77 |
| Sensitivity | 0,78 | 0,71-0,86 | 0,67 | 0,51-0,80 |
| Specificity | 0,76 | 0,73-0,78 | 0,75 | 0,73-0,78 |
| Kappa Cohens | 0,15 | 0,12-0,19 | 0,11 | 0,07-0,15 |
| MALE | FEMALE | |||||||
|---|---|---|---|---|---|---|---|---|
| Bag | Out of Bag | Bag | Out of Bag | |||||
| Median | IQR | Median | IQR | Median | IQR | Median | IQR | |
| AUC | 0,6 | 0,52-0,60 | 0,61 | 0,50-0,71 | 0,9 | 0,87-0,92 | 0,91 | 0,86-0,94 |
| Accuracy | 0,69 | 0,29-0,59 | 0,67 | 0,29-0,57 | 0,83 | 0,8-0,86 | 0,82 | 0,77-0,85 |
| sensitivity | 0,8 | 0,62-1 | 0,5 | 0-0,76 | 1 | 0,89-1 | 0,8 | 0,6-1 |
| specificity | 0,68 | 0,26-0,76 | 0,68 | 0,26-0,76 | 0,83 | 0,79-0,86 | 0,83 | 0,77-0,86 |
| Kappa Cohens | 0,07 | 0,03-0,12 | 0 | 0,0-0,02 | 0,31 | 0,23-0,38 | 0,21 | 0,14-0,29 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).